- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04964934
Fase III-studie ter beoordeling van AZD9833+ CDK4/6-remmer in HR+/HER2-MBC met detecteerbare ESR1m vóór progressie (SERENA-6) (SERENA-6)
Een dubbelblinde, gerandomiseerde fase III-studie om de overstap naar AZD9833 (een orale SERD van de volgende generatie) + CDK4/6-remmer (Palbociclib of Abemaciclib) versus continue aromataseremmer (letrozol of anastrozol) + CDK4/6-remmer in HR+/ te beoordelen HER2-MBC-patiënten met detecteerbare ESR1-mutatie zonder ziekteprogressie tijdens 1L-behandeling met aromataseremmer+ CDK4/6-remmer-A ctDNA Begeleide vroege-switchstudie
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Studie Overzicht
Toestand
Interventie / Behandeling
- Geneesmiddel: AZD9833
- Geneesmiddel: Anastrozole placebo
- Geneesmiddel: Letrozole placebo
- Geneesmiddel: Palbociclib
- Geneesmiddel: Abemaciclib
- Geneesmiddel: Luteinizing hormone-releasing hormone (LHRH) agonist
- Geneesmiddel: Ribociclib
- Geneesmiddel: AZD9833 Placebo
- Geneesmiddel: Anastrozole
- Geneesmiddel: Letrozole
Gedetailleerde beschrijving
Breast cancer is the most common type of cancer among women. In people with breast cancer, the body is not able to control the growth of some cells. These extra cells can form tumors in the breast. When tumor cells move to different parts of the body this is called advanced cancer. Researchers are looking for better ways to treat advanced breast cancer.
This trial will look at six drugs: palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and AZD9833. AZD9833 is the trial drug, and is the only drug not yet approved for use. Palbociclib, abemaciclib and ribociclib work in the same way and are a type of cancer drug called a CDK4/6 inhibitor. Letrozole and anastrozole work in the same way and are both a type of cancer drug called an aromatase inhibitor (AI). CDK4/6 inhibitors and AIs work together to block the tumor's ability to grow. These drugs have been approved for combined use in people with advanced breast cancer that is HR-positive and HER2-negative. But if people get mutations in the ESR1 gene, it can make the AI and CDK4/6 inhibitor treatment work less well.
The trial drug, AZD9833, is designed to work with a CDK4/6 inhibitor in the same way that an AI does. Researchers think that AZD9833 might work better with a CDK4/6 inhibitor than an AI does in people who get mutations in their ESR1 gene.
Participants in this trial will have already been receiving one of the following combinations of a CDK4/6 inhibitor and an AI:
- palbociclib + anastrozole
- palbociclib + letrozole
- abemaciclib + anastrozole
- abemaciclib + letrozole
- ribociclib + anastrozole
- ribociclib + letrozole
During the trial, participants will remain on the same CDK4/6 inhibitor that they were taking before the trial.
In this trial, the researchers want to find out how well switching a participant with an ESR1 gene mutation from an AI (letrozole or anastrozole) to AZD9833 works in the treatment of advanced breast cancer that is HR-positive and HER2-negative.
The researchers will look at which trial treatment helps the participants live longer with the cancer before it gets worse.
The researchers also want to know more about how safe AZD9833 is.
The trial participants will be split into 2 groups:
- Participants in Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo
- Participants in Group B will receive an AI, a CDK4/6 inhibitor, and a placebo
A placebo looks like a treatment but does not have any medicine in it.
A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.
The participants will take their trial treatments over 28-day cycles, with a placebo and either AZD9833 or an AI taken once daily by mouth for all 28 days. If the participant is taking abemaciclib, they will take it twice daily by mouth for all 28 days. If the participant is taking palbociclib or ribociclib, they will take it once daily by mouth for 21 days and then stop taking it for the final 7 days of the cycle. The participant will then repeat the 28-day cycle receiving the trial treatment in the same way for as long as they are in the trial.
Participants will visit their trial site regularly throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.
Participants will take their trial treatment until their cancer gets worse or they decide to leave the trial.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Birtinya, Australië, 4575
- Research Site
-
Darlinghurst, Australië, 2010
- Research Site
-
-
-
-
-
Leuven, België, 3000
- Research Site
-
Liège, België, 4000
- Research Site
-
Namur, België, 5000
- Research Site
-
-
-
-
-
Haskovo, Bulgarije, 6300
- Research Site
-
Panagyurishte, Bulgarije, 4500
- Research Site
-
Pleven, Bulgarije, 5804
- Research Site
-
Plovdiv, Bulgarije, 4004
- Research Site
-
Sofia, Bulgarije, 1431
- Research Site
-
Sofia, Bulgarije, 1407
- Research Site
-
Sofia, Bulgarije, 1527
- Research Site
-
Sofia, Bulgarije, 1330
- Research Site
-
Sofia, Bulgarije, 1303
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Research Site
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Research Site
-
-
Quebec
-
Lévis, Quebec, Canada, G6V 3Z1
- Research Site
-
Montreal, Quebec, Canada, H2X 0C1
- Research Site
-
Montreal, Quebec, Canada, H3T 1E2
- Research Site
-
Montreal, Quebec, Canada, H1T 2M4
- Research Site
-
Québec, Quebec, Canada, G1S 4L8
- Research Site
-
-
-
-
-
Ansbach, Duitsland, 91522
- Research Site
-
Augsburg, Duitsland, 86156
- Research Site
-
Bonn, Duitsland, 53111
- Research Site
-
Chemnitz, Duitsland, 09116
- Research Site
-
Dresden, Duitsland, 01307
- Research Site
-
Erlangen, Duitsland, 91054
- Research Site
-
Essen, Duitsland, 45130
- Research Site
-
Freiburg im Breisgau, Duitsland, 79110
- Research Site
-
Hösbach, Duitsland, 63768
- Research Site
-
Immenstadt im Allgäu, Duitsland, 87509
- Research Site
-
Koblenz, Duitsland, 56068
- Research Site
-
Leipzig, Duitsland, 4103
- Research Site
-
Mannheim, Duitsland, 68167
- Research Site
-
München, Duitsland, 80634
- Research Site
-
Paderborn, Duitsland, 33098
- Research Site
-
Ratingen, Duitsland, 40878
- Research Site
-
Ravensburg, Duitsland, 88212
- Research Site
-
Regensburg, Duitsland, 93053
- Research Site
-
Stade, Duitsland, 21680
- Research Site
-
Tübingen, Duitsland, 72076
- Research Site
-
Ulm, Duitsland, 89075
- Research Site
-
-
-
-
-
Avignon, Frankrijk, 84918
- Research Site
-
Brest, Frankrijk, 29200
- Research Site
-
Clermont-Ferrand, Frankrijk, 63050
- Research Site
-
Dijon, Frankrijk, 21079
- Research Site
-
Limoges, Frankrijk, 83000
- Research Site
-
Lorient, Frankrijk, 56322
- Research Site
-
Lyon, Frankrijk, 69373
- Research Site
-
Marseille, Frankrijk, 13273
- Research Site
-
Metz-Tessy, Frankrijk, 74370
- Research Site
-
Nîmes, Frankrijk, 30029
- Research Site
-
Paris, Frankrijk, 75248
- Research Site
-
Rouen, Frankrijk, 76021
- Research Site
-
Saint-Cloud, Frankrijk, 92210
- Research Site
-
Saint-Herblain, Frankrijk, 44805
- Research Site
-
Toulouse, Frankrijk, 31100
- Research Site
-
Tours, Frankrijk, 37000
- Research Site
-
Vandœuvre-lès-Nancy, Frankrijk, 54519
- Research Site
-
Vantoux, Frankrijk, 57070
- Research Site
-
Villejuif, Frankrijk, 94805
- Research Site
-
-
-
-
-
Budapest, Hongarije, 1122
- Research Site
-
Budapest, Hongarije, 1062
- Research Site
-
Miskolc, Hongarije, 3526
- Research Site
-
Szekszárd, Hongarije, 7100
- Research Site
-
Szolnok, Hongarije, 5000
- Research Site
-
Zalaegerszeg, Hongarije, 8900
- Research Site
-
-
-
-
-
Beersheba, Israël, 8410101
- Research Site
-
Haifa, Israël, 3109601
- Research Site
-
Jerusalem, Israël, 91120
- Research Site
-
Petah Tikva, Israël, 494142
- Research Site
-
Ramat Gan, Israël, 5262000
- Research Site
-
-
-
-
-
Bergamo, Italië, 24127
- Research Site
-
Bologna, Italië, 40138
- Research Site
-
Florence, Italië, 50134
- Research Site
-
Meldola, Italië, 47014
- Research Site
-
Milan, Italië, 20141
- Research Site
-
Milan, Italië, 20132
- Research Site
-
Misterbianco, Italië, 95045
- Research Site
-
Naples, Italië, 80131
- Research Site
-
Padova, Italië, 35128
- Research Site
-
Roma, Italië, 00168
- Research Site
-
Rozzano, Italië, 20089
- Research Site
-
-
-
-
-
Chiba, Japan, 260-8717
- Research Site
-
Chūōku, Japan, 104-0045
- Research Site
-
Hidaka-shi, Japan, 350-1298
- Research Site
-
Hirakata-shi, Japan, 573-1191
- Research Site
-
Kitaadachi-gun, Japan, 362-0806
- Research Site
-
Kumamoto, Japan, 860-8556
- Research Site
-
Kōtoku, Japan, 135-8550
- Research Site
-
Matsuyama, Japan, 791-0280
- Research Site
-
Nagoya, Japan, 464-8681
- Research Site
-
Nagoya, Japan, 467-8602
- Research Site
-
Niigata, Japan, 951-8566
- Research Site
-
Osaka, Japan, 540-0006
- Research Site
-
Osaka, Japan, 541-8567
- Research Site
-
Ota-shi, Japan, 373-8550
- Research Site
-
Sapporo, Japan, 003-0804
- Research Site
-
Shinagawa-ku, Japan, 142-8666
- Research Site
-
Shinjuku-ku, Japan, 162-8655
- Research Site
-
Takasaki-shi, Japan, 370-0829
- Research Site
-
Takatsuki-shi, Japan, 569-8686
- Research Site
-
Tsukuba, Japan, 305-8577
- Research Site
-
Yokohama, Japan, 241-8515
- Research Site
-
-
-
-
-
Drammen, Noorwegen, 3004
- Research Site
-
Oslo, Noorwegen, 0450
- Research Site
-
-
-
-
-
Graz, Oostenrijk, 8036
- Research Site
-
Innsbruck, Oostenrijk, 6020
- Research Site
-
Salzburg, Oostenrijk, 5020
- Research Site
-
Vienna, Oostenrijk, 1130
- Research Site
-
-
-
-
-
Bydgoszcz, Polen, 85-796
- Research Site
-
Gdynia, Polen, 81-519
- Research Site
-
Koszalin, Polen, 75-581
- Research Site
-
Lodz, Polen, 90-302
- Research Site
-
Poznan, Polen, 60-693
- Research Site
-
Rzeszów, Polen, 35-001
- Research Site
-
Tomaszów Mazowiecki, Polen, 97-200
- Research Site
-
Warsaw, Polen, 02-781
- Research Site
-
-
-
-
-
Guimarães, Portugal, 4835-044
- Research Site
-
Lisbon, Portugal, 1649-035
- Research Site
-
Lisbon, Portugal, 1400-038
- Research Site
-
Lisbon, Portugal, 1500-650
- Research Site
-
Lisbon, Portugal, 1449-005
- Research Site
-
Loures, Portugal, 2674-514
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
Porto, Portugal, 4200-319
- Research Site
-
Porto, Portugal, 4200-072
- Research Site
-
Vila Nova de Gaia, Portugal, 4434-502
- Research Site
-
-
-
-
-
Moscow, Rusland, 111123
- Research Site
-
Moscow, Rusland, 143423
- Research Site
-
Moscow, Rusland, 129090
- Research Site
-
Nizhny Novgorod, Rusland, 603126
- Research Site
-
Podolsk, Rusland, 142100
- Research Site
-
Saint Petersburg, Rusland, 197758
- Research Site
-
Saint Petersburg, Rusland, 194017
- Research Site
-
-
-
-
-
Banská Bystrica, Slowakije, 974 01
- Research Site
-
Bratislava, Slowakije, 833 01
- Research Site
-
Košice, Slowakije, 041 91
- Research Site
-
Michalovce, Slowakije, 07101
- Research Site
-
Partizánske, Slowakije, 958 01
- Research Site
-
-
-
-
-
A Coruña, Spanje, 15009
- Research Site
-
Badalona, Spanje, 08003
- Research Site
-
Barcelona, Spanje, 8035
- Research Site
-
L'Hospitalet de Llobregat, Spanje, 08908
- Research Site
-
Madrid, Spanje, 28041
- Research Site
-
Madrid, Spanje, 28040
- Research Site
-
Murcia, Spanje, 30008
- Research Site
-
Málaga, Spanje, 29010
- Research Site
-
Sant Joan Despí, Spanje, 08970
- Research Site
-
Seville, Spanje, 41013
- Research Site
-
Valencia, Spanje, 46010
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Research Site
-
Taichung, Taiwan, 40705
- Research Site
-
Tainan, Taiwan, 70403
- Research Site
-
Tainan, Taiwan, 710
- Research Site
-
Taipei, Taiwan, 100
- Research Site
-
Taipei, Taiwan
- Research Site
-
Taipei, Taiwan, 11490
- Research Site
-
Taipei, Taiwan, 23561
- Research Site
-
Taipei, Taiwan, 11259
- Research Site
-
Taipei, Taiwan, 110
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Adana, Turkije (Türkiye), 01120
- Research Site
-
Ankara, Turkije (Türkiye), 06100
- Research Site
-
Ankara, Turkije (Türkiye), 06520
- Research Site
-
Ankara, Turkije (Türkiye), 06010
- Research Site
-
Ankara, Turkije (Türkiye), 06340
- Research Site
-
Cordaleo, Turkije (Türkiye), 35575
- Research Site
-
Izmir, Turkije (Türkiye), 35100
- Research Site
-
Izmir, Turkije (Türkiye), 35360
- Research Site
-
Kadıkoy/Istanbul, Turkije (Türkiye), 34722
- Research Site
-
Kayseri, Turkije (Türkiye), 38039
- Research Site
-
-
-
-
-
Blackpool, Verenigd Koninkrijk, FY3 8NR
- Research Site
-
Cambridge, Verenigd Koninkrijk, CB2 0QQ
- Research Site
-
London, Verenigd Koninkrijk, SW3 6JJ
- Research Site
-
London, Verenigd Koninkrijk, WC1N 3BG
- Research Site
-
Manchester, Verenigd Koninkrijk, M20 4BX
- Research Site
-
Newport, Verenigd Koninkrijk, NP10 8FZ
- Research Site
-
Nottingham, Verenigd Koninkrijk, NG5 1PB
- Research Site
-
Portsmouth, Verenigd Koninkrijk, PO6 3LY
- Research Site
-
Reading, Verenigd Koninkrijk, RG2 9LH
- Research Site
-
Sheffield, Verenigd Koninkrijk, S10 2SJ
- Research Site
-
Sutton, Verenigd Koninkrijk, SM2 5PT
- Research Site
-
Taunton, Verenigd Koninkrijk, TA1 5DA
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85054
- Research Site
-
-
Arkansas
-
Hot Springs, Arkansas, Verenigde Staten, 71913
- Research Site
-
Little Rock, Arkansas, Verenigde Staten, 72205
- Research Site
-
-
California
-
Long Beach, California, Verenigde Staten, 90806
- Research Site
-
San Diego, California, Verenigde Staten, 92123
- Research Site
-
Santa Rosa, California, Verenigde Staten, 92805
- Research Site
-
-
Colorado
-
Grand Junction, Colorado, Verenigde Staten, 81501
- Research Site
-
Lone Tree, Colorado, Verenigde Staten, 80124
- Research Site
-
-
Florida
-
Fort Myers, Florida, Verenigde Staten, 33901
- Research Site
-
Jacksonville, Florida, Verenigde Staten, 32256
- Research Site
-
Jacksonville, Florida, Verenigde Staten, 32224
- Research Site
-
St. Petersburg, Florida, Verenigde Staten, 33705
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30318
- Research Site
-
Atlanta, Georgia, Verenigde Staten, 30322
- Research Site
-
Atlanta, Georgia, Verenigde Staten, 30342
- Research Site
-
-
Illinois
-
Park Ridge, Illinois, Verenigde Staten, 60068
- Research Site
-
-
Indiana
-
Fort Wayne, Indiana, Verenigde Staten, 46804
- Research Site
-
Indianapolis, Indiana, Verenigde Staten, 46250
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21202
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Research Site
-
Fairhaven, Massachusetts, Verenigde Staten, 02719
- Research Site
-
Foxborough, Massachusetts, Verenigde Staten, 02035
- Research Site
-
Milford, Massachusetts, Verenigde Staten, 01757
- Research Site
-
South Weymouth, Massachusetts, Verenigde Staten, 02190
- Research Site
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Research Site
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Research Site
-
-
Mississippi
-
Oxford, Mississippi, Verenigde Staten, 38655
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64111
- Research Site
-
St Louis, Missouri, Verenigde Staten, 63110
- Research Site
-
-
Montana
-
Billings, Montana, Verenigde Staten, 59101
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68130
- Research Site
-
-
New Jersey
-
Camden, New Jersey, Verenigde Staten, 08103
- Research Site
-
Ridgewood, New Jersey, Verenigde Staten, 07450
- Research Site
-
-
New York
-
Brooklyn, New York, Verenigde Staten, 11215
- Research Site
-
East Syracuse, New York, Verenigde Staten, 13057
- Research Site
-
New Hyde Park, New York, Verenigde Staten, 11042
- Research Site
-
New York, New York, Verenigde Staten, 10065
- Research Site
-
New York, New York, Verenigde Staten, 11355
- Research Site
-
Shirley, New York, Verenigde Staten, 11967
- Research Site
-
-
North Carolina
-
Goldsboro, North Carolina, Verenigde Staten, 27534
- Research Site
-
-
Ohio
-
Canton, Ohio, Verenigde Staten, 44710
- Research Site
-
Cincinnati, Ohio, Verenigde Staten, 45220
- Research Site
-
Columbus, Ohio, Verenigde Staten, 43219
- Research Site
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97213
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Research Site
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15213
- Research Site
-
York, Pennsylvania, Verenigde Staten, 17403
- Research Site
-
-
South Carolina
-
Greenville, South Carolina, Verenigde Staten, 29607
- Research Site
-
West Columbia, South Carolina, Verenigde Staten, 29169
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37916
- Research Site
-
Memphis, Tennessee, Verenigde Staten, 38120
- Research Site
-
Nashville, Tennessee, Verenigde Staten, 37203
- Research Site
-
-
Texas
-
Bedford, Texas, Verenigde Staten, 76022
- Research Site
-
Dallas, Texas, Verenigde Staten, 75246
- Research Site
-
Houston, Texas, Verenigde Staten, 77030
- Research Site
-
Houston, Texas, Verenigde Staten, 77024
- Research Site
-
Longview, Texas, Verenigde Staten, 75601
- Research Site
-
San Antonio, Texas, Verenigde Staten, 78240
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84106
- Research Site
-
-
Virginia
-
Midlothian, Virginia, Verenigde Staten, 23114
- Research Site
-
Norfolk, Virginia, Verenigde Staten, 23502
- Research Site
-
-
Washington
-
Tacoma, Washington, Verenigde Staten, 98405
- Research Site
-
-
Wisconsin
-
Waukesha, Wisconsin, Verenigde Staten, 53226
- Research Site
-
-
-
-
-
Cheonan-si, Zuid -Korea, 31151
- Research Site
-
Daegu, Zuid -Korea, 42415
- Research Site
-
Goyang-si, Zuid -Korea, 10408
- Research Site
-
Seongnam-si, Zuid -Korea, 13620
- Research Site
-
Seongnam-si, Zuid -Korea, 463-712
- Research Site
-
Seoul, Zuid -Korea, 02841
- Research Site
-
Seoul, Zuid -Korea, 03080
- Research Site
-
Seoul, Zuid -Korea, 03722
- Research Site
-
Seoul, Zuid -Korea, 05505
- Research Site
-
Seoul, Zuid -Korea, 06273
- Research Site
-
Seoul, Zuid -Korea, 06351
- Research Site
-
Seoul, Zuid -Korea, 06591
- Research Site
-
-
-
-
-
Bern, Zwitserland, CH-3010
- Research Site
-
Chur, Zwitserland, CH-7000
- Research Site
-
Winterthur, Zwitserland, 8401
- Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
INCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:
- Have advanced breast cancer that is not able to be treated with surgery or radiation;
- Have an ESR1 mutation in their cancer;
- Have breast cancer that is HR-positive and HER2-negative;
- Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
- Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
- Are able to do their daily activities;
- Are at least 18.
Full list of inclusion criteria:
- Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent;
- Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
- Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
- Eastern Cooperative Oncology Group performance status of 0 or 1;
- ESR1m detected by central testing of ctDNA with Guardant360® CDx;
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
- Adequate organ and marrow function.
EXCLUSION CRITERIA:
INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:
- Had certain types of tumors in the past that may come back;
- Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
- Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.
Full list of exclusion criteria:
- Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
- Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease;
- Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
- Patient with known or family history of severe heart disease;
- Previous treatment with AZD9833, investigational SERDs or fulvestrant;
- Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
- Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: AZD9833 + palbociclib, abemaciclib or ribociclib
The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily) |
Dosage formulation: AZD9833 tablets will be administered orally Dosage formulation: anastrozole placebo tablets will be administrated orally. Dosage formulation: letrozole placebo tablets will be administered orally. Dosage formulation: palbociclib tablets/capsules will be administered orally Dosage formulation: abemaciclib tablets will be administered orally Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist. Dosage formulation: ribociclib tablets will be administered orally |
|
Actieve vergelijker: Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib
The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily) |
Dosage formulation: palbociclib tablets/capsules will be administered orally Dosage formulation: abemaciclib tablets will be administered orally Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist. Dosage formulation: ribociclib tablets will be administered orally Dosage formulation: AZD9833 placebo tablets will be administrated orally. Dosage formulation: anastrozole tablets will be administered orally. Dosage formulation: letrozole tablets will be administered orally. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)
Tijdsspanne: From randomization until the earlier of the progression event or death (approximately 2 years)
|
PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death. |
From randomization until the earlier of the progression event or death (approximately 2 years)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival 2 (PFS2)
Tijdsspanne: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
|
PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death. |
From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
|
|
Overall survival (OS)
Tijdsspanne: From randomization until the date of death due to any cause (approximately 5 years)
|
The OS is defined as the time from randomization to death due to any cause. |
From randomization until the date of death due to any cause (approximately 5 years)
|
|
Chemotherapy free survival
Tijdsspanne: From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
|
Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause. |
From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
|
|
Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1
Tijdsspanne: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
|
ORR is defined as the proportion of patients who have a complete response (CR) or partial response (PR), as determined by the investigator at local site per RECIST 1.1. |
From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
|
|
Clinical benefit rate at 24 weeks (CBR24)
Tijdsspanne: At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
|
CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for At least 23 weeks after randomisation for each patient to allow for an early assessment within the assessment window (1 week window for RECIST assessment) |
At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
|
|
Change from baseline in EORTC QLQ-C30 scale scores
Tijdsspanne: From baseline until second progression (approximately 5 years)
|
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden. |
From baseline until second progression (approximately 5 years)
|
|
Change from baseline in EORTC QLQ-BR23 scale scores
Tijdsspanne: From baseline until second progression (approximately 5 years)
|
Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden. |
From baseline until second progression (approximately 5 years)
|
|
Plasma concentration of AZD9833 at specified timepoints
Tijdsspanne: on Day 15 for each patient
|
To assess the steady state PK of AZD9833 in combination with palbociclib or abemaciclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration. |
on Day 15 for each patient
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):569-580. doi: 10.1056/NEJMoa2502929. Epub 2025 Jun 1.
- Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. Epub 2023 Apr 18.
- Brufsky A, Park YH, Bidard FC, Mayer EL, Janni W, Ma C, Cristofanilli M, Bianchini G, Iwata H, Fasching PA, Nowecki Z, Pascual J, Chen SC, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Jung KH, Kikawa Y, Baird RD, Habash R, Sugarman R, Fox S, Selvi Miralles M, Huang Bartlett C, Turner N. SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy. Oncologist. 2026 Aug 6;31(9):oyag278. doi: 10.1093/oncolo/oyag278.
- Turner NC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Brufsky AM, Fasching PA, Nowecki Z, Pascual J, Karadurmus N, Gal-Yam E, Chung WP, Im SA, Zambelli A, Dalenc F, Oliveira M, Ishiguro H, Huang CS, Klinowska T, Fox S, Morrow C, Robert L, Huang-Bartlett C, Bidard FC. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2026 Aug;27(8):941-958. doi: 10.1016/S1470-2045(26)00287-1. Epub 2026 Jul 13.
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Neoplasmata
- Dubbelblind
- Fase III
- Metastatisch
- Ribociclib
- Antineoplastische middelen
- Borstneoplasmata
- Fysiologische effecten van medicijnen
- Gerandomiseerd
- Endocriene therapie
- Letrozol
- Palbociclib
- Neoplasmata per site
- Borst ziekten
- Abemaciclib
- Anastrozol
- Multicenter
- AZD9833
- Mondelinge SERD van de volgende generatie
- Antagonisten
- Oestrogeenreceptorantagonisten
- Hormoon antagonisten
- camizestrant
- ESR1m
- Wissel van behandeling
- Endocriene weerstand
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplastische processen
- Huidziektes
- Pathologische aandoeningen, tekenen en symptomen
- Huid- en bindweefselaandoeningen
- Neoplasmata
- Borstneoplasmata
- Neoplasma metastase
- Borst ziekten
- Neoplasmata per site
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Hypofyse hormoonafgooiende hormonen
- Hypothalamische hormonen
- Peptide hormonen
- Neuropeptiden
- Peptiden
- Aminozuren, peptiden en eiwitten
- Oligopeptiden
- Zenuwweefsel eiwitten
- Eiwitten
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Azoles
- Nitriles
- Triazoles
- Letrozol
- Anastrozol
- Gonadotropine-afgevende hormoon
- abemaciclib
- ribociclib
- palbociclib
- AZD9833
Andere studie-ID-nummers
- D8534C00001
- 2023-503990-39-00 (Andere identificatie: EU CT number)
- 2021-000546-17 (EudraCT-nummer)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-tijdsbestek voor delen
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-toegangscriteria voor delen
When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .